Your browser doesn't support javascript.
loading
Heart rate recovery is an important predictor of outcomes in patients with connective tissue disease-associated pulmonary hypertension.
Minai, Omar A; Nguyen, Quyen; Mummadi, Srinivas; Walker, Esteban; McCarthy, Kevin; Dweik, Raed A.
Affiliation
  • Minai OA; Department of Pulmonary, Allergy, and Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Nguyen Q; Department of Medicine, Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Mummadi S; Department of Pulmonary Medicine, Oregon Health and Science University, Portland, Oregon, USA.
  • Walker E; Department of Qualitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA.
  • McCarthy K; Department of Pulmonary, Allergy, and Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Dweik RA; Department of Pulmonary, Allergy, and Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Pulm Circ ; 5(3): 565-76, 2015 Sep.
Article in En | MEDLINE | ID: mdl-26401258
ABSTRACT
Reduced heart rate recovery (HRR) after exercise is associated with increased mortality in cardiac and pulmonary diseases. We sought to evaluate the association between HRR after the 6-minute walk test (6MWT) and outcomes in patients with connective tissue disease-associated pulmonary hypertension (CTD-PH). Data were obtained by review of the medical records. HRR was defined as the difference in heart rate at the end of the 6MWT and after 1 minute (HRR1), 2 minutes (HRR2), and 3 minutes (HRR3) of rest. All patients with pulmonary hypertension and a diagnosis of systemic sclerosis, systemic lupus erythematosus, or mixed connective tissue disease who underwent the 6MWT between August 1, 2009, and October 30, 2011, were included (n = 66). By Kaplan-Meier analysis, HRR1, HRR2, and HRR3 at different cutoff points were all good predictors, with HRR1 of <16 being the best predictor of time to clinical worsening (log-rank P < 0.0001), hospitalization (log-rank P = 0.0001), and survival (log-rank P < 0.003). By proportional hazards regression, patients with HRR1 of <16 were at increased risk of clinical worsening (hazard ratio [HR] 6.4 [95% confidence interval (CI) 2.6-19.2]; P < 0.0001], hospitalization (HR 6.6 [95% CI 2.4-23]; P < 0.0001), and death (HR 4.5 [95% CI 1.6-15.7]; P = 0.003). Patients in the highest tercile (HRR1 of ≥19) were unlikely to have a clinical worsening event (HR 0.1 [95% CI 0.04-0.5]; P = 0.001], to be hospitalized (HR 0.1 [95% CI 0.02-0.5]; P = 0.001), or to die (HR 0.3 [95% CI 0.07-0.9]; P = 0.04]. In conclusion, in patients with CTD-PH, abnormal HRR1 (defined as HRR1 of <16) after the 6MWT is a strong predictor of clinical worsening, time to clinical worsening, survival, and hospitalization.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies / Risk_factors_studies Language: En Journal: Pulm Circ Year: 2015 Document type: Article Affiliation country: United States Publication country: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies / Risk_factors_studies Language: En Journal: Pulm Circ Year: 2015 Document type: Article Affiliation country: United States Publication country: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA